Perampanel
- Generic Name
- Perampanel
- Brand Names
- Fycompa
- Drug Type
- Small Molecule
- Chemical Formula
- C23H15N3O
- CAS Number
- 380917-97-5
- Unique Ingredient Identifier
- H821664NPK
- Background
Perampanel is a noncompetitive AMPA glutamate receptor antagonist. It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures. The FDA label includes an important black-boxed warning of serious or life-threatening behaviora...
- Indication
Perampanel is indicated for the treatment of partial-onset seizures with or without secondarily generalized seizures in epileptic patients four years of age and older. It is also indicated as an adjunct in the treatment of primary generalized tonic-clonic seizures in epileptic patients aged 12 years and older.
- Associated Conditions
- Epilepsy, Primary Generalized Tonic-Clonic Seizures, Partial-Onset Seizures
- Associated Therapies
- -
Perampanel in Focal Status Epilepticus
- Conditions
- Interventions
- First Posted Date
- 2020-03-16
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 1
- Registration Number
- NCT04309721
- Locations
- 🇫🇷
Urgences, CHU Lille (Hôpital Roger Salengro), Lille, France
🇫🇷Neurologie, Centre Hospitalier de Versailles - André Mignot, Versailles, Ile De France, France
🇫🇷Hôpital Pitié Salpêtrière - ICU, Paris, France
A Study of Perampanel as Add-on Therapy in Adult and Adolescent Participants With Focal Seizures
- First Posted Date
- 2020-02-06
- Last Posted Date
- 2020-02-06
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 243
- Registration Number
- NCT04257604
A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy
- Conditions
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2023-02-09
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 191
- Registration Number
- NCT04252846
- Locations
- 🇮🇹
Fondazione PTV Policlinico Tor Vergata, Roma, Lazio, Italy
🇷🇺Krasnoyarsk State Medical University n.a. V.F. Voyno-Ysenetskiy, Krasnoyarsk, Russian Federation
🇷🇺City Clinical Hospital #1 n.a. N.I.Pirogov, Moscow, Russian Federation
A Study to Evaluate the Safety and Efficacy of Fycompa® (Perampanel) as Add-on Therapy in Participants With Epilepsy
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 117
- Registration Number
- NCT04230044
A Study to Evaluate the Effectiveness of Perampanel as Only Add-on Treatment in Participants With Primary or Secondarily Generalized Tonic-clonic Seizures
- First Posted Date
- 2019-12-17
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- Eisai GmbH
- Target Recruit Count
- 187
- Registration Number
- NCT04202159
- Locations
- 🇩🇪
Eisai Trial Site #15, Bernau, Germany
🇩🇪Eisai Trial Site #8, Bielefeld, Germany
🇩🇪Eisai Trial Site #9, Bonn, Germany
Correlation of Serum Level of Perampanel (PER) Level to Cerebrospinal Fluid (CSF) Levels of PER
- First Posted Date
- 2019-10-08
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Carilion Clinic
- Target Recruit Count
- 25
- Registration Number
- NCT04118829
- Locations
- 🇺🇸
Carilion Clinic, Roanoke, Virginia, United States
A Study to Assess Safety and Efficacy of Perampanel in Indian Participants as an Adjunctive Treatment in Partial Onset Seizures With or Without Secondary Generalized Seizures in Participants With Epilepsy Aged 12 Years or Older
- First Posted Date
- 2019-02-11
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Eisai Pharmaceuticals India Pvt. Ltd
- Target Recruit Count
- 200
- Registration Number
- NCT03836924
- Locations
- 🇮🇳
BGS Gleneagles Global Hospitals, Bengaluru, Karnataka, India
🇮🇳Seth G S Medical College & KEM Hospital, Mumbai, Maharashtra, India
🇮🇳Brain Clinic, Jasleen Hospital, Nagpur, Maharashtra, India
Perampanel Single Ascending Dose Transcranial Magnetic Stimulation Biomarker Study in Amyotrophic Lateral Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2019-01-04
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 22
- Registration Number
- NCT03793868
- Locations
- 🇺🇸
Mayo Clinic, Jacksonville, Florida, United States
A Study of Intravenous Perampanel in Japanese Participants With Epilepsy
- First Posted Date
- 2018-11-27
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 21
- Registration Number
- NCT03754582
- Locations
- 🇯🇵
Eisai trial site 9, Omura, Nagasaki, Japan
🇯🇵Eisai trial site 10, Hiroshima, Japan
🇯🇵Eisai trial site 4, Yamagata, Japan
Efficacy and Safety of Perampanel in Combination in Glioma-refractory Epilepsy
- Conditions
- Interventions
- First Posted Date
- 2018-08-17
- Last Posted Date
- 2022-06-27
- Lead Sponsor
- Assistance Publique Hopitaux De Marseille
- Registration Number
- NCT03636958
- Locations
- 🇫🇷
Assistance Publique Des Hopitaux de Marseille, Marseille, Paca, France
🇫🇷Department of Epileptology and Cerebral Rhythmology, Hôpital La Timone, APHM, Marseille, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.